EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY-NC 4.0

Efficacy and safety of denosumab administered at 6-monthly versus 9-monthly intervals in postmenopausal osteoporosis: Protocol for a randomized, open-label, blinded endpoint clinical trial

Ranvijay Singh, Rimesh Pal, Sanjay Kumar Bhadada, Pinaki Dutta, Urmila Yadav, Richa Rattan, Naresh Sachdeva, Snigdha Kumari, Tulika Singh

Therapeutic Advances in Endocrinology and Metabolism · 2026-10 · 19

DOI: 10.1177/20420188261504166 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Therapeutic Advances in Endocrinology and Metabolism, online erschienen am 02.11.2026. Verfasst von Ranvijay Singh und 8 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Endocrine Society of India.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Denosumab is widely used for postmenopausal osteoporosis and is conventionally administered at 6-month intervals. However, pharmacodynamic and pharmacokinetic evidence suggests that suppression of bone turnover may persist beyond this duration. In a prior prospective study from our group, bone turnover marker-guided delayed dosing was not associated with early skeletal harm. Whether a longer fixed dosing interval can maintain skeletal efficacy while reducing treatment burden remains uncertain.

Objectives

To compare the efficacy and safety of denosumab administered at fixed 6-monthly versus 9-monthly intervals in postmenopausal women with osteoporosis.

Design

Prospective, randomized, open-label, blinded endpoint (PROBE) clinical trial.

Methods

Postmenopausal women aged ≥50 years with DXA-defined osteoporosis and/or prior fragility fracture will be randomized (1:1) to receive denosumab 60 mg subcutaneously every 6 months or every 9 months for 18 months (four vs. three doses), along with calcium and cholecalciferol supplementation. Participants will be followed for an additional 12 months after treatment discontinuation, with predefined criteria for rescue therapy using zoledronic acid. The primary endpoint is percent change in areal bone mineral density at the lumbar spine at 24 months. Secondary outcomes include incident fragility fractures, changes in trabecular bone score, HR-pQCT-derived microarchitecture and bone strength, longitudinal changes in bone turnover markers, and requirement for rescue therapy. Safety outcomes include hypocalcemia, osteonecrosis of the jaw, atypical femoral fractures, incident vertebral fractures during the extended-interval treatment period, and post-discontinuation skeletal events. Ethics The study has received institutional ethics approval, and written informed consent will be obtained from all participants.

Discussion

This trial is designed to provide the first randomized evidence evaluating whether a fixed extended dosing interval of denosumab can preserve skeletal efficacy. The findings are expected to inform optimization of dosing strategies, with potential implications for treatment burden and cost. Registration Prospectively registered in Clinical Trial Registry of India (CTRI/2025/12/099664) dated 22-12-2025.

Förderung

  • Endocrine Society of India

Zitieren

APA

Singh, R., Pal, R., Bhadada, S. K., Dutta, P., Yadav, U., Rattan, R., Sachdeva, N., Kumari, S., & Singh, T. (2026). Efficacy and safety of denosumab administered at 6-monthly versus 9-monthly intervals in postmenopausal osteoporosis: Protocol for a randomized, open-label, blinded endpoint clinical trial. Therapeutic Advances in Endocrinology and Metabolism, 19. https://doi.org/10.1177/20420188261504166

Vancouver

Singh R, Pal R, Bhadada SK, Dutta P, Yadav U, Rattan R, et al. Efficacy and safety of denosumab administered at 6-monthly versus 9-monthly intervals in postmenopausal osteoporosis: Protocol for a randomized, open-label, blinded endpoint clinical trial. Therapeutic Advances in Endocrinology and Metabolism. 2026;19. doi:10.1177/20420188261504166

BibTeX
@article{Singh2026,
  author = {Singh, Ranvijay and Pal, Rimesh and Bhadada, Sanjay Kumar and Dutta, Pinaki and Yadav, Urmila and Rattan, Richa and Sachdeva, Naresh and Kumari, Snigdha and Singh, Tulika},
  title = {Efficacy and safety of denosumab administered at 6-monthly versus 9-monthly intervals in postmenopausal osteoporosis: Protocol for a randomized, open-label, blinded endpoint clinical trial},
  journal = {Therapeutic Advances in Endocrinology and Metabolism},
  year = {2026},
  volume = {19},
  doi = {10.1177/20420188261504166}
}
Kostenlos starten →